Source comparison
Top CJC-1295 Studies: Clinical Research Comparison
Teichman 2005 (JCEM) Single-dose, placebo-controlled, 18 healthy males 60 mcg/kg CJC-1295 DAC subcutaneous GH and IGF-1 AUC over 14 days Mean GH elevated to 1.3 ng/mL at 24h, remained >0.8 ng/mL through day 7 Peak IGF-1 increase of 45–55% at day 7–10 First hum
This comparison does not assign a generated winner or score.
- Teichman 2005 (JCEM)
- Single-dose, placebo-controlled, 18 healthy males
- 60 mcg/kg CJC-1295 DAC subcutaneous
- GH and IGF-1 AUC over 14 days
- Mean GH elevated to 1.3 ng/mL at 24h, remained >0.8 ng/mL through day 7
- Peak IGF-1 increase of 45–55% at day 7–10
- First human trial demonstrating albumin-bound GHRH analogue extends GH elevation beyond 10 days from single injection
- Ionescu 2006
- Multiple-dose (4 weeks), 30 vs 60 mcg/kg weekly
- 60 mcg/kg weekly × 4
- Cumulative IGF-1 effect and GH pulsatility
- Nocturnal GH pulse amplitude decreased 40%, trough GH doubled
- Trough IGF-1 reached 1.8–2.1× baseline by week 3
- Demonstrated cumulative effect without tolerance. Trough levels increased with repeated dosing
- Alba 2012
- Partial GH deficiency cohort vs healthy controls
- 60 mcg/kg CJC-1295 DAC
- IGF-1 response stratified by baseline GH status
- GH response 89% above baseline in deficient group vs 45% in healthy controls
- IGF-1 elevation inversely correlated with baseline IGF-1 (r = −0.68)
- Response magnitude depends on endogenous GH reserve. Greater effect in those with lower baseline secretion
- Comparative 2014 (GH & IGF Research)
- Crossover design: Mod GRF (1-29) 3×/day vs CJC-1295 DAC 1×/week
- 100 mcg Mod GRF vs 60 mcg/kg DAC
- Pulsatility preservation vs tonic elevation
- Mod GRF: +60–80% pulse amplitude, no trough change; DAC: +140% mean GH, −35% pulse amplitude
- Both groups +55–65% IGF-1, but Mod GRF returned to baseline in 48h vs 12–14 days for DAC
- Mod GRF preserves pulsatility; DAC creates sustained tonic elevation. Fundamentally different GH secretion patterns
- Meta-Analysis 2018 (Peptides)
- Systematic review of 14 GHRH analogue trials
- Variable across studies
- Duration of IGF-1 elevation and adverse event rates
- Albumin-binding analogues showed 2.5–3.5× longer IGF-1 elevation
- Sustained elevation associated with 40–50% higher edema and carpal tunnel rates
- Longer half-life trades efficacy duration for higher IGF-1-mediated side effect risk